Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

7TM Pharma reports positive results from phase I/II clinical study of obinepitide for obesity

Nov. 30, 2007

Antares and Population Council report positive results from phase I trial of contraceptive gel

Nov. 30, 2007

BioMarin files IND with FDA for PEG-PAL for the treatment of phenylketonuria

Nov. 30, 2007

Kissei patents novel agents for the treatment of gout

Nov. 30, 2007

Eisai submits Japanese NDA application for KES-524 for obesity management

Nov. 29, 2007

CSL Behring reaches primary endpoint in IMPACT phase III clinical study of C1-INH

Nov. 29, 2007

Israeli Government awards grant to Modigene for hGH-CTP development program

Nov. 29, 2007

Bristol-Myers Squibb advances growth hormone secretagogue to clinical development

Nov. 29, 2007

Novel agents for treating diabetes and related disorders disclosed in recent patent literature

Nov. 29, 2007

GlaxoSmithKline obtains exclusive U.S. OTC marketing rights to Mevacor

Nov. 28, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...